Abstract
Psychiatric disorders have long and dominantly been regarded to be induced by disturbances of neuronal networks including synapses and neurotransmitters. Thus, the effects of psychotropic drugs such as antipsychotics and antidepressants have been understood to modulate synaptic regulation via receptors and transporters of neurotransmitters such as dopamine and serotonin. Recently, microglia, immunological/inflammatory cells in the brain, have been indicated to have positive links to psychiatric disorders. Positron emission tomography (PET) imaging and postmortem studies have revealed microglial activation in the brain of neuropsychiatric disorders such as schizophrenia, depression and autism. Animal models of neuropsychiatric disorders have revealed the underlying microglial pathologies. In addition, various psychotropic drugs have been suggested to have direct effects on microglia. Until now, the relationship between microglia, neurotransmitters and psychiatric disorders has not been well understood. Therefore, in this review, at first, we summarize recent findings of interaction between microglia and neurotransmitters such as dopamine, serotonin, norepinephrine, acetylcholine and glutamate. Next, we introduce up-to-date knowledge of the effects of psychotropic drugs such as antipsychotics, antidepressants and antiepileptics on microglial modulation. Finally, we propose the possibility that modulating microglia may be a key target in the treatment of various psychiatric disorders. Further investigations and clinical trials should be conducted to clarify this perspective, using animal in vivo studies and imaging studies with human subjects.
Keywords: Microglia, antipsychotics, antidepressants, antiepileptics, minocycline, BDNF, dopamine, serotonin, norepinephrine, schizophrenia, depression, epilepsy, psychiatry
Current Medicinal Chemistry
Title:Neurotransmitters, Psychotropic Drugs and Microglia: Clinical Implications for Psychiatry
Volume: 20 Issue: 3
Author(s): T. A. Kato, Y. Yamauchi, H. Horikawa, A. Monji, Y. Mizoguchi, Y. Seki, K. Hayakawa, H. Utsumi and S. Kanba
Affiliation:
Keywords: Microglia, antipsychotics, antidepressants, antiepileptics, minocycline, BDNF, dopamine, serotonin, norepinephrine, schizophrenia, depression, epilepsy, psychiatry
Abstract: Psychiatric disorders have long and dominantly been regarded to be induced by disturbances of neuronal networks including synapses and neurotransmitters. Thus, the effects of psychotropic drugs such as antipsychotics and antidepressants have been understood to modulate synaptic regulation via receptors and transporters of neurotransmitters such as dopamine and serotonin. Recently, microglia, immunological/inflammatory cells in the brain, have been indicated to have positive links to psychiatric disorders. Positron emission tomography (PET) imaging and postmortem studies have revealed microglial activation in the brain of neuropsychiatric disorders such as schizophrenia, depression and autism. Animal models of neuropsychiatric disorders have revealed the underlying microglial pathologies. In addition, various psychotropic drugs have been suggested to have direct effects on microglia. Until now, the relationship between microglia, neurotransmitters and psychiatric disorders has not been well understood. Therefore, in this review, at first, we summarize recent findings of interaction between microglia and neurotransmitters such as dopamine, serotonin, norepinephrine, acetylcholine and glutamate. Next, we introduce up-to-date knowledge of the effects of psychotropic drugs such as antipsychotics, antidepressants and antiepileptics on microglial modulation. Finally, we propose the possibility that modulating microglia may be a key target in the treatment of various psychiatric disorders. Further investigations and clinical trials should be conducted to clarify this perspective, using animal in vivo studies and imaging studies with human subjects.
Export Options
About this article
Cite this article as:
A. Kato T., Yamauchi Y., Horikawa H., Monji A., Mizoguchi Y., Seki Y., Hayakawa K., Utsumi H. and Kanba S., Neurotransmitters, Psychotropic Drugs and Microglia: Clinical Implications for Psychiatry, Current Medicinal Chemistry 2013; 20 (3) . https://dx.doi.org/10.2174/0929867311320030003
DOI https://dx.doi.org/10.2174/0929867311320030003 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mining for Protein Kinase Substrates: Integration of Biochemistry, Genetics and Proteomics
Current Proteomics The New Patient and Responsible Self-Medication Practices: A Critical Review
Current Drug Safety Allopregnanolone Increases the Number of Dopaminergic Neurons in Substantia Nigra of a Triple Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research The Non-ABC Drug Transporter RLIP76 (RALBP-1) Plays a Major Role in the Mechanisms of Drug Resistance
Current Drug Metabolism Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research On Chemical Structures with Potent Antiepileptic/Anticonvulsant Profile
Mini-Reviews in Medicinal Chemistry Metabotropic GABAB Receptors New Challenges in Drug Design
Current Medicinal Chemistry - Central Nervous System Agents Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Selective Agonists and Antagonists for Kainate Receptors
Mini-Reviews in Medicinal Chemistry Cofilin Rod Formation in Neurons Impairs Neuronal Structure and Function
CNS & Neurological Disorders - Drug Targets Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier
Current Drug Metabolism Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Beneficial Effect of Rice Bran Extract Against Rotenone-Induced Experimental Parkinson’s Disease in Rats
Current Molecular Pharmacology Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence
CNS & Neurological Disorders - Drug Targets 2,3-Disubtituted Thiazolidin-4-ones: Novel Class of Anticonvulsant Agents
Letters in Drug Design & Discovery